Trim35 is a promising prognostic biomarker in DLBCL, and future studies should be conducted to further uncover the detailed mechanism by which the ubiquitination of clock proteins is related to remodeling of the tumor microenvironment and treatment response. This evidence concerns the gene TRIM35 and diffuse large B-cell lymphoma.